A randomized, open-label study of the effect of Herceptin plus Arimidex compared with Arimidex alone on progression-free survival in patients with HER2-positive and hormone-receptor positive metastatic breast cancer

Trial Profile

A randomized, open-label study of the effect of Herceptin plus Arimidex compared with Arimidex alone on progression-free survival in patients with HER2-positive and hormone-receptor positive metastatic breast cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Trastuzumab (Primary) ; Anastrozole
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TAnDEM
  • Sponsors Roche
  • Most Recent Events

    • 10 Aug 2012 Company added in association field as reported by ClinicalTrials.gov.
    • 10 Aug 2012 Company added in association field as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top